文献速递神经肿瘤

WHO 2016版脑肿瘤分类更新、分子标志物及临床结局对多形性黄色星形细胞瘤的影响

Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
PubMed 文献 · J Neurooncol · 2017-11-16

本研究回顾2006至2016年间37例组织学确诊的多形性黄色星形细胞瘤(PXA)患者的结局,分析临床、病理及分子标志物的影响。中位随访33个月,3年与5年总生存率分别为80.2%和74%。全切除(23例,62%)患者3年无进展生存率为85.6%,显著优于次全切除(13例,35%)的32.3%(p=0.001)。

要点

  • 全切除患者3年无进展生存率85.6%,显著优于次全切除的32.3%(p=0.001)。
  • PXA II级3年无进展生存率80.2%,显著优于间变性PXA的32%(p=0.007)。
  • BRAFV600E突变患者3年无进展生存率51.9%,非突变患者为73%。

核心结论

  • 本研究数据可能为未来研究提供有价值的见解和基准。

研究设计与样本

  • 2006年至2016年间37例组织学确诊为多形性黄色星形细胞瘤(PXA)的患者构成研究队列。
  • 所有患者均接受最大安全范围切除;切除良好且年轻的患者接受观察。
  • 具有高MIB-1指数(>5%)、残留病灶或复发等非典型特征的患者接受辅助放疗。
  • 间变性PXA患者接受辅助放疗和全身治疗。

主要发现

  • 诊断时中位年龄为20岁(范围4-45岁)。
  • 中位随访33个月时,3年和5年总生存率分别为80.2%和74%。
  • 全切除(23例,62%)患者3年无进展生存率为85.6%,显著优于次全切除(13例,35%)的32.3%(p=0.001)。
  • PXA II级较间变性PXA组无进展生存率显著更优(3年估计值80.2% vs 32%;p=0.007)。
  • 27例BRAFV600E检测成功患者中13例存在突变(48%);突变患者3年无进展生存率和总生存率分别为51.9%和76.9%,非突变患者分别为73%和75%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present outcomes of pleomorphic xanthoastrocytoma (PXA) and correlate the impact of clinical, pathologic and molecular markers. Between 2006 and 2016, 37 patients with histologically verified PXA form the study cohort. All underwent maximal safe resection; those who had good resection and young age were observed. Adjuvant radiotherapy was given in patients with some atypical features such as high MIB-1 index (> 5%), residual disease or at recurrence. Patients with anaplastic PXA were administered adjuvant radiotherapy and systemic therapy. Median age at diagnosis was 20 years (range 4-45). At median follow-up of 33 months, 3-year and 5-year overall survival (OS) was 80.2 and 74% respectively. Patients who underwent GTR (23 cases, 62%) had significantly better 3-year PFS of 85.6% compared to 32.3% (p = 0.001) achieved with STR (13 cases, 35%). PFS was significantly superior in PXA grade II as compared to anaplastic PXA group (3-year estimates 80.2 vs. 32%; p = 0.007). 13 out of 27 patients where BRAFV600E testing was successful showed a mutation (48%). 3-year PFS and OS survival in BRAFV600E mutated patients was 51.9 and 76.9% compared to 73 and 75% in BRAFV600E non-mutated patients, respectively. No patient had IDH1 mutation. This data may provide valuable insights and act as a benchmark for future studies.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tonse R, Gupta T, Epari S, et al. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. J Neurooncol. 2017. PMID: 29147864. doi:10.1007/s11060-017-2658-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。